Does oxybutynin alter plaques, amyloid beta peptides and behavior in a mouse model of Alzheimers disease?
Author(s): Klausner AP, Sharma S, Fletcher S, Neff P, Yang SK, Son H, Tuttle JB, Steers WD Affiliation(s): Department of Neuroscience, University of Virginia Health System, Charlottesville, Virginia, USA. apklausner@vcu.edu Publication date & source: 2008-03, J Urol., 179(3):1173-7. Publication type: PURPOSE: In elderly patients oxybutynin (Sigma-Aldrich) is commonly used to treat overactive bladder despite increased prevalence of Alzheimer’s disease in this population. We determined whether oxybutynin altered plaque formation, amyloid beta peptide expression and behavior in a transgenic mouse model of Alzheimer’s disease expressing the mutant human presenilin 1 (deltaE9) and a chimeric mouse/human amyloid precursor protein (APPswe). MATERIALS AND METHODS: Mice were treated for 30 days in an acute experiment or 5 months in a chronic experiment with oxybutynin (30 mg/kg) or vehicle. Behavioral testing was performed monthly with the elevated plus maze (Med Associates, St. Albans, Vermont
